Clinical Trials
| No. | Tumor Type | Stage | Study Title | Principal Investigator | Details | Status |
|---|---|---|---|---|---|---|
| 1 | Lung Cancer | IV | A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer | Dr Toh Chee Keong | #NCT04262856 | Open |
| 2 | Breast cancer | IV | A Randomized, multicentre, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of ER(+), HER(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease | Dr Lynette Ngo | #NCT04478266 | Open |
| 3 | Hepatocellular carcinoma | IV | A Phase III, Randomized Double-blind, Placebo-controlled, Multicentre Study of Transarterial Chemoembolization (TACE) in Combination With either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) | Dr Choo Su Pin | #NCT03778957 Emerald-1 Trial Patient Information | Open |
| 4 | Endometrial cancer | IV | A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer(DUO-E) | Dr Lynette Ngo | #NCT04269200 | Open |
| 5 | Gastric cancer | IV | A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined with Chemotherapy versus Placebo Combined with Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer | Dr Choo Su Pin | #NCT04139135 | Closed |
| 6 | Hepatocellular carcinoma | IV | A randomized, open-label, multi-center phase III clinical study to evaluate the safety and efficacy of Toripalimab (JS001) combined with Bevacizumab versus Sorafenib as first-line therapy for advanced hepatocellular carcinoma (HCC) | Dr Choo Su Pin | #NCT04723004 | Open |
| 7 | Hepatocellular carcinoma | IV | A phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who are at High Risk of Recurrence after Curative Hepatic Resection or Ablation (EMERALD 2) | Dr Choo Su Pin | #NCT03847428 | Open |
| 8 | Prostate cancer | IV | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) | Dr Toh Chee Keong | #NCT04446117 | Open |
| 9 | Lung cancer | IV | LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (LIQUIK) | Dr Toh Chee Keong | #NCT04703153 | Open |
| 10 | Breast cancer | IV | A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting | Dr Lynette Ngo | #NCT04494425 | Open |
| 11 | Esophageal cancer | IV | A 3-Arm, Randomized, Blinded, Active-controlled, Phase II Study of RO7121661, A PD1-LAG3 Bispecific Antibody, compared with Nivolumab in Participants with Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | Dr Choo Su Pin | #NCT04785820 | Open |